comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 03:54:08 - browse：5236

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Retired US general questions alleged Putin, Prigozhin meeting

focus

Wikipedia

WSS

AstraZeneca loses challenge to Medicare drug price negotiation

Charles Manson follower Leslie Van Houten released from prison after 53 years

Change Healthcare cyberattack outage could last weeks

What to know about OceanGate, the company behind the missing Titanic submersible

An inside look at PIPEs, biotech's buzzy new financing tool

Flu vaccine offering decent levels of protection this winter, new data show

knowledge

comprehensive

focus

Anesthesiologist group: stop taking Ozempic before surgery

International team creates first chimeric human

Peter Hotez and the public health issue of online harassment

How to address the problem of discarded donor organs

Supreme Court strikes down use of affirmative action

Why 40% Americans with Parkinson’s don’t see a neurologist

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Congress gives doctors Medicare pay bump

Hepatitis C has a cure — but many Americans still lack access to it

Why getting cancer drugs just got harder for rural patients

focus

RSV vaccines may be linked to small increased risk of developing GBS

Palantir health business leans on meeting customers’ needs

Petition to FDA: Get the lead out of consumer hair dyes

New research casts further doubt on a common procedure used with IVF

AstraZeneca loses challenge to Medicare drug price negotiation

Petition to FDA: Get the lead out of consumer hair dyes

hotspot

focus

Wikipedia

knowledge